Merrill keeps ZymoGenetics at buy

ZymoGenetics, Inc. was maintained at a buy rating by Merrill Lynch analyst Hari Sambasivam. The company's stock closed down 3% on March 30 on heavy volume. Merrill attributes some of the sell-off to speculation regarding a competing product to ZymoGenetics' rhThrombin. Omrix Biopharmaceuticals has a human-derived thrombin product in phase 3 development. The analyst believes given the choice between a human plasma derived product, and a recombinant product, physicians will chose the recombinant product. Shares of the Seattle pharmaceutical company were up 56 cents, or 2.66%, at $21.62 on volume of 536,251 shares versus the three-month running average of 543,505 shares. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.